How Competing Risks Affect the Epidemiological Relationship Between Vitamin D and Prostate Cancer Incidence? A Population-based Study

Overview

Journal Andrologia

Specialties Reproductive Medicine
Urology

Date 2022 Mar 1

PMID 35229338

Authors

Ari Voutilainen

Jyrki K Virtanen

Sari Hantunen

Tarja Nurmi

Petra Kokko

Tomi-Pekka Tuomainen

Affiliations

Soon will be listed here.

Abstract

We hypothesized that controversial results regarding the epidemiological relationship between circulating 25-hydroxyvitamin D, 25(OH)D, and risk of prostate cancer (PCA) incidence are partly due to competing risks. To test the hypothesis, we studied associations across 25(OH)D, PCA and death in 2578 middle-aged men belonging to the Kuopio Ischaemic Heart Disease Risk Factor Study. The men were free of cancer at baseline, and the mean (SD) follow-up time was 23.3 (9.1) years. During this period, 296 men had a PCA diagnosis, and 1448 men died without the PCA diagnosis. The absolute risk of developing PCA was highest in the highest 25(OH)D tertile (15%), whereas that of death was highest in the lowest 25(OH)D tertile (67%). A competing risk analysis showed that belonging to the highest 25(OH)D tertile increased the risk of PCA incidence and improved survival with the respective hazard ratios (HR) of 1.35 (95% CI = 1.07-1.70) and 0.79 (95% CI = 0.71-0.89). Adjusting for 10 covariates together with 25(OH)D did not significantly change the results, but the respective adjusted HRs for PCA and death were 1.20 and 0.87. To conclude, the competing risk analysis did not eliminate the direct relationship between 25(OH)D and PCA but rather strengthened it.

Citing Articles

Association of Vitamin D and Prostate Health Status in Men: An Analytical Cross-Sectional Study.

Reddy J, K A A, V M V, Prasath N, Ravat M Cureus. 2025; 16(12):e74959.

PMID: 39744261 PMC: 11693405. DOI: 10.7759/cureus.74959.

What is the most appropriate follow-up time for detecting the epidemiological relationship between coronary artery disease and its main risk factors: novel findings from a 35-year follow-up study.

Voutilainen A, Brester C, Kolehmainen M, Tuomainen T Coron Artery Dis. 2023; 34(5):320-331.

PMID: 37139560 PMC: 10836792. DOI: 10.1097/MCA.0000000000001245.

Vitamin D Deficiency at Diagnosis Increases All-Cause and Prostate Cancer-specific Mortality in Jamaican Men.

McGrowder D, Tulloch-Reid M, Coard K, McCaw-Binns A, Ferguson T, Aiken W Cancer Control. 2022; 29:10732748221131225.

PMID: 36180132 PMC: 9527998. DOI: 10.1177/10732748221131225.

How competing risks affect the epidemiological relationship between vitamin D and prostate cancer incidence? A population-based study.

Voutilainen A, Virtanen J, Hantunen S, Nurmi T, Kokko P, Tuomainen T Andrologia. 2022; 54(6):e14410.

PMID: 35229338 PMC: 9540471. DOI: 10.1111/and.14410.

References

Virtanen J, Nurmi T, Voutilainen S, Mursu J, Tuomainen T . Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland. Eur J Nutr. 2010; 50(5):305-12. DOI: 10.1007/s00394-010-0138-3. View

Brandstedt J, Almquist M, Manjer J, Malm J . Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control. 2012; 23(8):1377-85. DOI: 10.1007/s10552-012-9948-3. View

Manson J, Bassuk S, Buring J . Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. J Steroid Biochem Mol Biol. 2019; 198:105522. PMC: 7089819. DOI: 10.1016/j.jsbmb.2019.105522. View

Murphy A, Nyame Y, Martin I, Catalona W, Hollowell C, Nadler R . Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res. 2014; 20(9):2289-99. PMC: 4104275. DOI: 10.1158/1078-0432.CCR-13-3085. View

Albanes D, Mondul A, Yu K, Parisi D, Horst R, Virtamo J . Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev. 2011; 20(9):1850-60. PMC: 3188814. DOI: 10.1158/1055-9965.EPI-11-0403. View

Yin L, Raum E, Haug U, Arndt V, Brenner H . Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009; 33(6):435-45. DOI: 10.1016/j.canep.2009.10.014. View

Thederan I, Chandrasekar T, Tennstedt P, Knipper S, Kuehl L, Tilki D . Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort. Eur Urol Focus. 2021; 7(5):973-979. DOI: 10.1016/j.euf.2020.12.005. View

Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J . Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(2):302-7. DOI: 10.1158/1055-9965.EPI-06-0777. View

Haggstrom C, Stocks T, Nagel G, Manjer J, Bjorge T, Hallmans G . Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology. 2014; 25(6):823-8. PMC: 4222792. DOI: 10.1097/EDE.0000000000000174. View

10.

Weinstein S, Mondul A, Kopp W, Rager H, Virtamo J, Albanes D . Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer. 2012; 132(12):2940-7. PMC: 3594427. DOI: 10.1002/ijc.27969. View

11.

Salonen J, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R . High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992; 86(3):803-11. DOI: 10.1161/01.cir.86.3.803. View

12.

Li J, Siegel D, King J . Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014. Ann Epidemiol. 2018; 28(5):328-330. PMC: 6080305. DOI: 10.1016/j.annepidem.2018.03.001. View

13.

Travis R, Crowe F, Allen N, Appleby P, Roddam A, Tjonneland A . Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol. 2009; 169(10):1223-32. PMC: 2675646. DOI: 10.1093/aje/kwp022. View

14.

Lakka T, Venalainen J, Rauramaa R, Salonen R, Tuomilehto J, Salonen J . Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med. 1994; 330(22):1549-54. DOI: 10.1056/NEJM199406023302201. View

15.

Berry S, Ngo L, Samelson E, Kiel D . Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010; 58(4):783-7. PMC: 2873048. DOI: 10.1111/j.1532-5415.2010.02767.x. View

16.

Khankari N, Shu X, Wen W, Kraft P, Lindstrom S, Peters U . Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. PLoS Med. 2016; 13(9):e1002118. PMC: 5012582. DOI: 10.1371/journal.pmed.1002118. View

17.

Li H, Stampfer M, Hollis J, Mucci L, Gaziano J, Hunter D . A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007; 4(3):e103. PMC: 1831738. DOI: 10.1371/journal.pmed.0040103. View

18.

Kassi E, Stavropoulos S, Kokkoris P, Galanos A, Moutsatsou P, Dimas C . Smoking is a significant determinant of low serum vitamin D in young and middle-aged healthy males. Hormones (Athens). 2014; 14(2):245-50. DOI: 10.14310/horm.2002.1521. View

19.

Yaturu S, Zdunek S, Youngberg B . Vitamin d levels in subjects with prostate cancer compared to age-matched controls. Prostate Cancer. 2013; 2012:524206. PMC: 3530178. DOI: 10.1155/2012/524206. View

20.

Dimitrakopoulou V, Tsilidis K, Haycock P, Dimou N, Al-Dabhani K, Martin R . Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. BMJ. 2017; 359:j4761. PMC: 5666592. DOI: 10.1136/bmj.j4761. View